Figure 6: In vivo efficacy of SC81458 and SC83288 in P. falciparum-infected humanized NSG mice.
From: SC83288 is a clinical development candidate for the treatment of severe malaria
NSG mice engrafted with human erythrocytes were infected with the P. falciparum strains 3D7 (a,c) or W2 (b,d). The compounds SC81458 (a,b) or SC83288 (c,d) were administered i.p. once per day over 4 days starting on day 7 post infection. Parasitemia was assessed each day from day 2 post infection up to 12 days. The mean±s.e.m. of four mice in each treatment group are shown.
